Value and the pricing of innovation

November 23, 2016 Christoph Graener

Balancing the cost of innovation and ensuring access to high-quality, effective medical treatment continues to be a challenge for all modern healthcare systems. Significant shifts in global and local market dynamics, policy and politics are prompting a discussion about other dimensions of value, be they economic, social, or scientific. How can biotech innovators best demonstrate the value of their therapies so that outcomes are measurable and relevant to all stakeholders?

  

  

Moderator: Joseph Damond – Biotechnology Innovation Organization (BIO)

  • Kate Bingham – SV Life Sciences Advisers
  • Jörg Möller – Bayer AG
  • Rehan Verjee – Merck KGaA
  • Juergen Windeler – Institute for Quality and Efficiency in Health Care, IQWiG

Previous Article
Denali deal and F-star’s innovative asset centric business model
Denali deal and F-star’s innovative asset centric business model

Jane Dancer, chief business officer at F-star, discusses F-star's asset-centric business strategy and the c...

Next Article
The new frontier: Aging and health

As older populations become the norm in many countries, healthy aging involves proactive prevention and tre...